The primary objective of the phase 1 open-label, dose-escalation study (NCT03451162) utilizing a 3 + 3 design was to evaluate safety and tolerability of DHES0815A in patients with advanced or metastatic HER2+ BC. The gene discussed is ERBB2; the disease is breast cancer.